Clinical-grade ATR inhibitor experiments support this hypothesis, showing ATRi’s effect on IFN-stimulated genes in two DZ-like DLBCL cell lines, alongside with negative modulation of DZ spatial signature genes. This evidence concerns the gene IFNA1 and diffuse large B-cell lymphoma.